Hepatitis
Conference Coverage
HCV patients with early-stage hepatocellular carcinoma can achieve SVR
Among patients with hepatocellular carcinoma, rates of sustained viral response to direct-acting regimens for hepatitis C virus were 79% for...
Conference Coverage
VIDEO: Appealing DAA denials is worth it for hepatitis C patients
BOSTON – Though criteria for insurance approval for direct-acting antivirals for hepatitis C virus are loosening, many patients are still denied...
Conference Coverage
Sofosbuvir/velpatasvir improved patient-reported outcomes, knocked out HCV genotypes 1-6
BOSTON – When given with ribavirin, a fixed-dose combination of sofosbuvir/velpatasvir (Epclusa) achieved a sustained viral response at 12 weeks (...
Conference Coverage
Tumor boards linked to improved survival in hepatocellular carcinoma
BOSTON – Veterans were about 13% less likely to die within 5 years of hepatocellular carcinoma diagnosis when multidisciplinary tumor boards...
Conference Coverage
Direct-acting antiretrovirals in genotype 1 HCV patients with mental health conditions safe, well tolerated
Clinicians can feel confident treating genotype 1 hepatitis C virus patients with comorbid psychiatric conditions using direct-acting...
Conference Coverage
VIDEO: Don’t be surprised by weight gain in men after HCV cure
BOSTON
Conference Coverage
Lack of health literacy and normal routine implicated in hepatitis B virus treatment nonadherence
BOSTON – Attention to health literacy, overcoming language barriers, and educating patients about the importance of maintaining a treatment...
News from the FDA/CDC
FDA approves tenofovir alafenamide for patients with chronic hepatitis B and liver disease
FDA has approved tenofovir alafenamide (marketed as Vemlidy by Gilead Sciences) for the treatment of adults with chronic hepatitis B virus...
Conference Coverage
Liver transplant waits shorter with DAAs
BOSTON – The rate of wait-listing for liver transplants for patients with hepatitis C and decompensated cirrhosis has decreased by over 30% since...
Conference Coverage
MBX-8025 yields ‘striking’ efficacy results but new safety signal in primary biliary cholangitis
BOSTON - The investigational peroxisome proliferator-activated receptor delta agonist MBX-8025 exhibited a "striking anticholestatic effect"...
From the Journals
Metabolic syndrome predicts cardiovascular events in HBV infection
Metabolic syndrome was associated with a fourfold rise in cardiovascular events among patients with chronic hepatitis B virus infection, according...